Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

Guo, Jian-You; Li, Changyu; Ruan, Yuanyuan; Sun, Meng; Qi, Xiaoli; Zhao, Baosheng; Luo, Fei

doi:10.1016/j.ejphar.2009.03.076

Cited by 131 publications

(85 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] In addition, the result of a recent basic study indicates that chronic celecoxib treatment reverse chronic unpredictable stress-induced depressive-like behavior. [15] There are several suggested mechanisms for antidepressant effects of COX2 inhibitors. COX2 inhibitors inhibit the synthesis of prostoglandins, in particular, PGE 2 .…”

Section: Discussionmentioning

confidence: 99%

“…[14] It has been reported that chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing COX-2 expression in rat brain. [15] In a prospective, 6-week, double-blind, add-on clinical trial with reboxetine, a noradrenergic reuptake inhibitor antidepressant, with or without the COX-2 inhibitor celecoxib, it has been reported that celecoxib significantly enhanced the antidepressant response to reboxetine. [16] In addition, another recent published trial has reported that adjunctive treatment with celecoxib may produce a rapid-onset antidepressant effect in bipolar disorder patients experiencing depressive or mixed episodes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

et al. 2009

View full text Add to dashboard Cite

Background: The pathophysiology of depression is associated with the hyperactivity of immune inflammatory responses. Cyclooxygenase-2 inhibitors such as celecoxib reduce the production of pro-inflammatory cytokines. The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of major depression in a six-week double blind and placebo controlled trial. Methods: Forty adult outpatients who met the DSM-IV-TR criteria for major depression participated in the trial. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18. Patients were allocated in a random fashion: 20 to fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 20 to fluoxetine 40 mg/ day plus placebo. Patients were assessed by a psychiatrist at baseline and after 1, 2, 4, and 6 weeks after the medication started. Results: Although both protocols significantly decreased the score of Hamilton Rating Scale for Depression over the trial period, the combination of fluoxetine and celecoxib showed a significant superiority over fluoxetine alone in the treatment of symptoms of major depression. There were no significant differences in the two groups in terms of observed side effects. Conclusion: The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with major depression and anti-inflammatory therapies should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Naturally, rodents avoid open spaces and prefer enclosed spaces, and by extension, the closed arms of the maze are preferred over the open arms. This may however change when the animal is under the influence of certain drugs; drugs with anxiolytic effects such as Diazepam caused shift in the behavioral response of animals toward exploration of the open arms (19). Our observations from the study are that artesunate and amodiaquine either alone or in combination altered the relative percentages of the time spent in the open versus closed arms, however, significant changes in the time spent were not seen until after the third dose was administered.…”

Section: Discussionmentioning

confidence: 41%

Oral Artesunate-Amodiaquine Combination Causes Anxiolysis and Impaired Cognition in Healthy Swiss Mice.

James¹

2013

IOSR-JPBS

View full text Add to dashboard Cite

“…Furthermore, even depressive impairments not primarily associated with inflammatory stimuli (e.g., depression induced by stress) are readily improved by anti-inflammatory medications [174,175]. Among various components of innate immunity, the inflammatory cytokine IL-1β has been particularly strongly implicated in inflammation-induced depression [176][177][178][179].…”

Section: Brain Inflammationmentioning

confidence: 99%

Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Kanner

Mazarati

Koepp³

2014

Neurotherapeutics

View full text Add to dashboard Cite

The last decade has witnessed a significant shift on our understanding of the relationship between psychiatric disorders and epilepsy. While traditionally psychiatric disorders were considered as a complication of the underlying seizure disorder, new epidemiologic data, supported by clinical and experimental research, have suggested the existence of a bidirectional relation between the two types of conditions: not only are patients with epilepsy at greater risk of experiencing a psychiatric disorder, but patients with primary psychiatric disorders are at greater risk of developing epilepsy. Do these data suggest that some of the pathogenic mechanisms operant in psychiatric comorbidities play a role in epileptogenesis? The aim of this article is to review the epidemiologic data that demonstrate that primary psychiatric disorders are more frequent in people who develop epilepsy, before the onset of the seizure disorder than among controls. The next question looks at the available data of pathogenic mechanisms of primary mood disorders and their potential for facilitating the development and/or exacerbation in the severity of epileptic seizures. Finally, we review data derived from experimental studies in animal models of depression and epilepsy that support a potential role of pathogenic mechanisms of mood disorders in the development of epileptic seizures and epileptogenesis. The data presented in this article do not yet establish conclusive evidence of a pathogenic role of psychiatric comorbidities in epileptogenesis, but raise important research questions that need to be investigated in experimental, clinical, and population-based epidemiologic research studies.

show abstract

Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

Cited by 131 publications

References 39 publications

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

Oral Artesunate-Amodiaquine Combination Causes Anxiolysis and Impaired Cognition in Healthy Swiss Mice.

Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Contact Info

Product

Resources

About